Psychopharmacologic therapies in dermatology: An update

Dermatologic Clinics

Volumn 23, Issue 4 SPEC. ISS., 2005, Pages 735-744

  Lee, Chai Sue ^a   Koo, John ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; ANTIARRHYTHMIC AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZATROPINE; BENZODIAZEPINE; BUSPIRONE; CITALOPRAM; DESIPRAMINE; DIPHENHYDRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; HYDROXYZINE; IMIPRAMINE; NEFAZODONE; OLANZAPINE; PAROXETINE; PIMOZIDE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACCOMMODATION; ADRENERGIC ACTIVITY; AGITATION; AKATHISIA; ANOREXIA; ANTICHOLINERGIC EFFECT; ANXIETY; ANXIETY DISORDER; ATOPIC DERMATITIS; ATRIOVENTRICULAR BLOCK; BITE; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DELUSIONAL DISORDER; DEPRESSION; DERMATOLOGY; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DIZZINESS; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; IRRITABILITY; LETHARGY; LIVER TOXICITY; MANIA; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PAIN; PATIENT CARE; PRIORITY JOURNAL; PRURITUS; PSYCHOCUTANEOUS DISEASE; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; QT PROLONGATION; RESTLESSNESS; REVIEW; RHINITIS; RIGIDITY; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SKIN BURNING SENSATION; SKIN DISEASE; SOCIAL PSYCHOLOGY; SOMNOLENCE; SUDDEN DEATH; TARDIVE DYSKINESIA; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 23844515779     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2005.05.015     Document Type: Review

References (49)

1. R. Fried Nonpharmacological treatments in psychodermatology J. Koo C.S. Lee Psychocutaneous medicine 2003 Marcel Dekker New York 411 426
2. J. Koo Psychodermatology: a practical manual for clinicians Curr Probl Dermatol 7 1995 199 234
3. J. Koo, and C.T. Pham Psychodermatology: practical guidelines on pharmacotherapy Arch Dermatol 128 1992 381 388
4. E.C. Settle Jr Antidepressant drugs: disturbing and potentially dangerous adverse effects J Clin Psychiatry 59 Suppl 16 1998 25 30
5. S.A. Montgomery Venlafaxine: a new dimension in antidepressant pharmacotherapy J Clin Psychiatry 54 1993 119 126
6. G.E. Clerc, P. Ruimy, and J. Verdeau-Pailles A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia Int Clin Psychopharmacol 9 1994 139 143
7. Y. Lecrubier, M. Bourin, and C.A. Moon Efficacy of venlafaxine in depressive illness in general practice Acta Psychiatr Scand 95 1997 485 493
8. P.H. Silverstone, A. Ravindran for the Venlafaxine XR 360 Canadian Study Group Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety J Clin Psychiatry 60 1999 22 28
9. K. Rickels, M.H. Pollack, and D.V. Sheehan Efficacy of extended-release Venlafaxine in nondepressed outpatients with generalize anxiety disorder Am J Psychiatry 157 2000 968 974
10. J.R. Davidson, R.L. DuPont, and D. Hedges Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder J Clin Psychiatry 60 1999 528 535
11. A.J. Gelenberg, R.B. Lydiard, and R.L. Rudolph Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial JAMA 238 2000 3052 3088
12. Haskins J.T., Aguiar L., Pallay A., et al for the Venlafaxine XR 210 Study Group. Double-blind, placebo-controlled study of once daily venlafaxine XR in outpatients with generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology. Paris France, Oct. 31-Nov. 4, 1998
13. Haskins J.T., Rudolph R., Aguiar L., et al for the Venlafaxine XR 214 Study Group. Double-blind, placebo-/comparator-controlled study of once daily venlafaxine XR and buspirone in outpatients with generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology. Paris, France, Oct. 31-Nov. 4, 1998
14. Haskins J.T., Rudolph R., Aguiar L., et al for the Venlafaxine XR 218 Study Group. Venlafaxine XR is an efficacious short- and long-term treatment for generalized anxiety disorder [abstract]. Presented at the 11th Congress of the European College of Neuropsychopharmacology. Paris, France, Oct. 31-Nov. 4, 1998
15. E. Richelson Biological basis of depression and therapeutic relevance J Clin Psychiatry 52 Suppl 1991 4 10
16. J.G. Modell, C.R. Katholi, and J.D. Modell Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline Clin Pharmacol Ther 61 1997 476 487
17. R.J. Kavoussi, R.T. Segraves, and A.R. Hughes Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients J Clin Psychiatry 58 1997 532 537
18. J.C. Ware, R. McBrayer, and V. Rose REM sleep enhancement by nefazodone, trazodone, and buspirone Sleep Res 22 1993 51
19. E.A. Nofzinger, C.F. Reynolds III, and M.E. Thase REM sleep enhancement by bupropion in depressed men Am J Psychiatry 152 1995 274 276
20. J. Davidson Seizures and bupropion: a review J Clin Psychiatry 50 1989 256 261
21. H.L. Leonard, S.E. Swedo, and M.C. Lenane A 2- to 7-year follow-up study of 54 obsessive-compulsive children and adolescents Arch Gen Psychiatry 50 1993 429 439
22. S.A. Rasmussen, and J.L. Eisen Treatment strategies for chronic and refractory obsessive-compulsive disorder J Clin Psychiatry 58 Suppl 13 1997 9 13
23. S.E. Swedo, J.L. Rapoport, and H. Leonard Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases Arch Gen Psychiatry 46 1989 335 341
24. H.L. Leonard New developments in the treatment of obsessive-compulsive disorder J Clin Psychiatry 58 Suppl 14 1997 39 45
25. M.H. Pollack, R. Zaninelli, and A. Goddard Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial J Clin Psychiatry 62 2001 350 357
26. D.S. Haskell, J.D. Gambill, and G. Gardos Doxepin or diazepam for anxious and anxious-depressed outpatients? J Clin Psychiatry 39 1978 135 139
27. R. Linskov Delusions of infestations treated with pimozide Acta Derm Venereol 65 1985 267 270
28. M.S. Driscoll, M.J. Rothe, and J.M. Grant-Kels Delusional parasitosis: a dermatologic psychiatric and pharmacologic approach JAAD 29 1993 1023 1033
29. A.F. Schatzberg, J.O. Cole, and C. DeBattista Manual of clinical psychopharmacology 3rd edition 1997 APA Press Washington, DC 154 155
30. H.Y. Meltzer New drugs for the treatment of schizophrenia Psychiatr Clin North Am 16 1993 365 385
31. A.Y. Deutch, B. Moghaddam, and R.B. Innis Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia Schizophr Res 4 1991 121 156
32. J. Gerlach New antipsychotics: classifications, efficacy and adverse effects Schizophr Bull 17 1991 289 309
33. K.L. Davis, R.S. Kahn, and G. Ko Dopamine in schizophrenia: a review and reconceptualization Am J Psychiatry 148 1991 1474 1486
34. Physicians' desk reference 1998 Medical Economics Montvale (NJ)
35. J.A. Lieberman Prediction of outcome in first-episode schizophrenia J Clin Psychiatry 54 Suppl 1993 13 17
36. D.E. Casey Side effect profiles of new antipsychotic agents J Clin Psychiatry 57 Suppl 11 1996 40S 45S
37. Prescribing information. Risperdal (risperidone) 1996 Janssen Pharmaceutica Titusville (NJ)
38. O.A. De Leon, K.M. Furmaga, and A.L. Canterbury Risperidone in the treatment of delusions of infestation Int J Psychiatry Med 27 1997 403 409
39. T.E. Hansen, D.E. Casey, and W.F. Hoffman Neuroleptic intolerance Schizophr Bull 23 1997 567 582
40. C.P. Watson, R.J. Evans, and K. Reed Amitriptyline versus placebo in postherpetic neuralgia Neurology 32 1982 671 673
41. M.B. Max, S.C. Schafer, and M. Culnane Amitriptyline, but not lorazepam, relieves postherpetic neuralgia Neurology 38 1988 1427 1432
42. C.P.N. Watson, M. Chipman, and K. Reed Amitriptyline versus maprotiline in postherpetic neuralgia : a randomized, double-blind crossover trial Pain 48 1992 29 36
43. C. Freinmann, M. Harris, and R. Cawley Psychogenic facial pain: presentation and treatment BMJ 288 1984 436 438
44. B.J. Urban, F.D. France, and E.K. Steinberger Long-term use of narcotic/antidepressant medication in the management of phantom limb pain Pain 24 1986 191 196
45. G. Eberhard, L. von Knorring, and H.L. Nilsson A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes Neuropsychobiology 19 1988 25 34
46. J.E. Bernstein, D.H. Whitney, and K. Soltani Inhibition of histamine-induced pruritus by topical tricyclic antidepressants J Am Acad Dermatol 5 1981 582 585
47. A. Figueiredo, C.A. Ribeiro, and M. Goncalo Mechanism of action of doxepin in the treatment of chronic urticaria Fund Clin Pharmacol 4 1990 147 158
48. F. Lawlor, and M.W. Greaves The development of recent strategies in the treatment of urticaria as a result of clinically oriented research Z Hautkr 65 1990 17 27
49. R. Kishore-Kumar, M.B. Max, and S.C. Schafer Desipramine relieves postherpetic neuralgia Clin Pharmacol Ther 47 1990 305 312